Cetirizine injection - JDP Therapeutics

Drug Profile

Cetirizine injection - JDP Therapeutics

Alternative Names: JDP-205; JDP-205 Al; JDP-207

Latest Information Update: 10 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JDP Therapeutics
  • Class Acetic acids; Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypersensitivity

Most Recent Events

  • 30 May 2017 JDP Therapeutics announces intention to submit NDA to the US FDA for Hypersensitivity (acute urticaria) in first half of 2018
  • 01 Mar 2017 Phase-III clinical trials in Hypersensitivity in USA (IV) (NCT02935699)
  • 01 Mar 2017 JDP Therapeutics initiated enrolment in a phase III trial in Hypersensitivity in Canada (IV) (NCT02935699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top